|
New Tablet Containing Two FDA Approved Anti-HIV Drugs For Antiretroviral Therapy Experienced HIV-1 Infected Subjects Clinical Trials Information presented on Clinical Trials Search is not designed to be a substitute for proven healthcare advice, travels to or treatment by using a genuine medical doctor. We are not physicians. Always confer with your doctor on New Tablet Containing Two FDA Approved Anti-HIV Drugs For Antiretroviral Therapy Experienced HIV-1 Infected Subjects conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. New Tablet Containing Two FDA Approved Anti-HIV Drugs For Antiretroviral Therapy Experienced HIV-1 Infected Subjects Clinical research trials and New Tablet Containing Two FDA Approved Anti-HIV Drugs For Antiretroviral Therapy Experienced HIV-1 Infected Subjects healthcare trials take place in many of cities across the United States of America. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally evaluate the effectiveness of new drugs. The function of the studies / undertakings is to answer specific human medical questions. Clinical trials are a popular means for mDs, government agencies, and private sector companies to find treatments for all forms of conditions, including New Tablet Containing Two FDA Approved Anti-HIV Drugs For Antiretroviral Therapy Experienced HIV-1 Infected Subjects. New Tablet Containing Two FDA Approved Anti-HIV Drugs For Antiretroviral Therapy Experienced HIV-1 Infected Subjects Clinical Trials and other clinical trials allow for volunteers to access medical treatment alternatives before they are available to the masses. Many times the test subjects undergo treatment for without cost, and occasionally they are compensated for their time. Occasionally there is a cost for a New Tablet Containing Two FDA Approved Anti-HIV Drugs For Antiretroviral Therapy Experienced HIV-1 Infected Subjects clinical trial. Test subjects oftentimes recieve the best healthcare possible for their New Tablet Containing Two FDA Approved Anti-HIV Drugs For Antiretroviral Therapy Experienced HIV-1 Infected Subjects condition. Hazards are a reality, nonetheless, and might include additional or frequent doctor trips, healthcare hazards (perhaps life-jeopardizing), and/or the treatment being ineffective. Trials are federally regulated with rigid guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "N" Clinical Trials Conditions > New Tablet Containing Two FDA Approved Anti-HIV Drugs For Antiretroviral Therapy Experienced HIV-1 Infected Subjects New Tablet Containing Two FDA Approved Anti-HIV Drugs For Antiretroviral Therapy Experienced HIV-1 Infected Subjects
New Tablet Containing Two FDA Approved Anti-HIV Drugs For Antiretroviral Therapy Experienced HIV-1 Infected Subjects
For Condition: HIV Infections
Status: No longer recruiting
Sponsor(s): Sponsor Name Pending ,
Synopsis: A 48-week study to investigate the safety and effectiveness of a new compact formulation of two already FDA approved anti-HIV drugs in subjects who have already been receiving treatment for their HIV infection.
Details:
Eligibility:
Study Type: Interventional, Treatment, Randomized, Open Label, Uncontrolled, Parallel Assignment, Safety/Efficacy Study
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: Inclusion Criteria: (The patient must meet the following criteria in order to be eligible for this study.) - Antiretroviral therapy (ART) experienced and currently receiving a stable regimen containing 3 nucleoside reverse transcriptase inhibitors (NRTIs), or 2 NRTIs plus a protease inhibitor (PI) or non-nucleoside reverse transcriptase inhibitors (NNRTI) for at least 3 months (there should be no significant ART modifications for at least 3 months and no ART change anticipated between Screening and initiation of the study therapy). - Patients must be naive to tenofovir. - HIV-1 RNA level > 1000 copies/ml on at least one occasion within 21 days of study entry. - A CD4 cell count > 50 cells/mm3. - Specified viral genotypes. Exclusion Criteria: (The patient cannot meet any of the following criteria in order to be eligible for this study.) - Pregnant or breast-feeding women. - Has an active diagnosis of AIDS. - Additional qualifying criteria to be determined by the physician.
Total Enrollment:
Location and Contact Information:
Study Site
Atlanta, Georgia, 30309
United States
Study Site
Nanterre Cedex, , 92014
France
Study Site
LeKremlin-Bictere, , 94275
France
Study Site
Hamburg, , 20099
Germany
Study Site
Houston, Texas, 77030
United States
Study Site
London, , NW3 2QG
United Kingdom
Study Site
Hampton, Virginia, 23666
United States
Study Site
Barcelona, , 08035
Spain
Study Site
Barcelona, , 08036
Spain
Study Site
Los Angeles, California, 90046
United States
Study Site
Bronx, New York, 10468
United States
Study Site
Vandoeuvre les Nancy Cedex, , 54411
France
Study Site
Columbia, South Carolina, 29206
United States
Study Site
Malaga, , 29600
Spain
Study Site
London, , W2 1NY
United Kingdom
Study Site
Berlin, , 12157
Germany
Study Site
Orlando, Florida, 32806
United States
Study Site
Charlotte, North Carolina, 28203
United States
Study Site
Leuven, , 3000
Belgium
Study Site
Madrid, , 28040
Spain
Study Site
Toronto, Ontario, M5B 1W8
Canada
Study Site
Ft. Myers, Florida, 33901
United States
Study Site
Atlanta, Georgia, 30308
United States
Study Site
Milano, , 20157
Italy
Study Site
Croydon, , CR77YE
United Kingdom
Study Site
London, , SE59RS
United Kingdom
Study Site
Levallois-Perret, , 92300
France
Study Site
Dallas, Texas, 75208
United States
Study Site
Modena, , 41100
Italy
Study Site
Paris, , 75651
France
Study Site
Augusta, Georgia, 30912
United States
Study Site
Verona, , 37126
Italy
Study Site
Perpignan Cedex, , 66046
France
Study Site
Brescia, , 25125
Italy
Study Site
Montreal, Quebec, H2L4P9
Canada
Study Site
LIEGE, , 4000
Belgium
Study Site
Madrid, , 28041
Spain
Study Site
Madrid, , 28046
Spain
Study Site
Coimbra, , 3049
Portugal
Study Site
Ft. Lauderdale, Florida, 33306
United States
Study Site
Jacksonville, Florida, 32206
United States
Study Site
St. Louis, Missouri, 63108
United States
Study Site
Bradenton, Florida, 34205
United States
Study Site
Stony Brook, New York, 11794
United States
Study Site
Philadelphia, Pennsylvania, 19107
United States
Study Site
Barcelona, , 08400
Spain
Study Site
London, , SW10 9NH
United Kingdom
Study Site
Toronto, Ontario, M4N 3M5
Canada
Study Site
London, , SW17 0QT
United Kingdom
Study Site
Paris, , 75010
France
Study Site
Lyon Cedex 03, , 69437
France
Study Site
Garches, , 92380
France
Study Site
Ste Foy, Quebec, G1V 4G2
Canada
Study Site
Philadelphia, Pennsylvania, 19102
United States
Study Site
Manchester, , M8 6RL
United Kingdom
Study Site
Plantation, Florida, 33317
United States
Study Site
Altamonte Springs, Florida, 32701
United States
Study Site
Montreal, Quebec, H2L 5B1
Canada
Study Site
Dallas, Texas, 75219
United States
Study Site
Beverly Hills, California, 90211
United States
Study Site
Lisboa, , 1150
Portugal
Study Site
Ft. Lauderdale, Florida, 33308
United States
Study Site
Hannover, , 30159
Germany
Study Site
Bobigny, , 93009
France
Study Site
Muenchen, , 80335
Germany
Study Site
New Orleans, Louisiana, 70115
United States
Study Site
Paris, , 75571
France
Study Site
Tampa, Florida, 33602
United States
Study Site
Atlanta, Georgia, 30339
United States
Study Site
Barcelona, , 08025
Spain
Study Site
Indianapolis, Indiana, 46202
United States
Study Site
Frankfurt, , 60596
Germany
Study Site
Cascais, , 2750
Portugal
Study Site
Faro, , 8000-386
Portugal
Study Site
Elche (Alicante), , 03202
Spain
Study Site
BRUXELLES, , 1000
Belgium
Study Site
Toronto, Ontario, M5G 2C4
Canada
Study Site
Ottawa, Ontario, K1N 6N5
Canada
Study Site
Oakland, California, 94602
United States
Study Site
Madrid, , 28041
Spain
Study Site
Hannover, , 30625
Germany
Study Site
Ferrara, , 44100
Italy
Study Site
Miami, Florida, 33140
United States
Study Site
Vancouver, British Columbia, V6Z 1Y6
Canada
Study Site
Lisboa, , 1769-001
Portugal
Study Site
Ft. Lauderdale, Florida, 33311
United States
Study Site
Akron, Ohio, 44304
United States
Study Site
Charleroi, , 6000
Belgium
Study Site
Braga, , 4700-308
Portugal
Study Site
Torino, , 10149
Italy
Study Site
Seattle, Washington, 98122
United States
Additional Information:
Study ID Numbers: CAL30001;
Study Start Date:
Record last reviewed: May 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00044577
Other Hiv Infections Studies:
1. A Clinical Trial of Alternating and Intermittent Regimens of 2',3'-Dideoxycytidine and 3'-Azido-3'-Deoxythymidine in the Treatment of Patients With AIDS and Advanced ARC
2. A Phase I, Placebo-Controlled, Dose-Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Thalidomide in Subjects With HIV-1 Infection
3. A Study of Timunox (Thymopentin) in HIV-Infected Patients Receiving Other Anti-HIV Drugs
4. The Effects of r-metHuIFN-gamma on the Lungs of Patients with AIDS
5. A Study on Amprenavir in Combination with Other Anti-HIV Drugs in HIV-Positive Patients
Related Studies:
Other HIV Infections Clinical Trials
Other Clinical Trials
Other Coimbra Clinical Trials
New Tablet Containing Two FDA Approved Anti-HIV Drugs For Antiretroviral Therapy Experienced HIV-1 Infected Subjects
|
|
|
|
|
|
|
|